Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova

admin by admin
November 14, 2024
in Stock
0
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

By Leroy Leo

(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a similar therapy from Summit Therapeutics (NASDAQ:SMMT) outperformed its blockbuster Keytruda in a late-stage trial in the country.

The deal allows Merck (NS:PROR) to take over development of privately held LaNova Medicines’ LM-299, the companies said on Thursday.

The drug candidate targets a protein called PD-1, which prevents the immune system from killing cancerous cells. It also curbs levels of another protein called VEGF, which can encourage tumor growth if found in excess.

Under the agreement, Merck will pay $588 million upfront. LaNova is also eligible to receive up to $2.7 billion in milestone payments.

In September, Summit and its partner Akeso released data that showed patients using their drug ivonescimab, which targets the same proteins, had significantly better survival rates than those on Keytruda.

This class of drug has been attracting increased interest for deals. On Wednesday, German drugmaker BioNTech (NASDAQ:BNTX) said it would acquire China’s Biotheus to gain access to its so-called bi-specific antibody that targets PD-1 and VEGF.

BMO analyst Evan Seigerman said the LaNova deal offers a hedge to Merck after the data shown by Summit and others.

“The company (Merck) still maintains the best-in-class PD-1 (in Keytruda) with a wall of clinical data and a rapidly advancing pipeline of other modalities to back it,” Seigerman added. “LaNova’s LM-299 simply adds another arrow to Merck’s arsenal.”

Keytruda became the world’s biggest-selling drug last year, with sales of about $25 billion. But the therapy is set to lose its patent protection by the end of the decade, pushing Merck to scout for deals.

This post appeared first on investing.com

Previous Post

General Mills to acquire Whitebridge Pet Brands for $1.45 billion

Next Post

Australian supermarket giants face class action over ‘dodgy’ discounts

admin

admin

Next Post
Australian supermarket giants face class action over ‘dodgy’ discounts

Australian supermarket giants face class action over ‘dodgy’ discounts

Trending News

Factbox-Bananas, cars, and clothes: US port labor dispute threatens range of products

Factbox-Bananas, cars, and clothes: US port labor dispute threatens range of products

September 30, 2024
Shopify merchants hit record $11.5 billion in Black Friday-Cyber Monday sales

Shopify merchants hit record $11.5 billion in Black Friday-Cyber Monday sales

December 3, 2024
China extends EU brandy anti-dumping investigation by three months

China extends EU brandy anti-dumping investigation by three months

December 25, 2024
Subscribe to Insightful Word


    Recent News

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    June 26, 2025
    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    June 26, 2025
    S&P 500 nears record high as Wall Street opens higher amid tech momentum

    S&P 500 nears record high as Wall Street opens higher amid tech momentum

    June 26, 2025
    Galaxy Digital launches $175 million fund to back DeFi and stablecoin startups

    Galaxy Digital launches $175 million fund to back DeFi and stablecoin startups

    June 26, 2025

    Recent News

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    June 26, 2025
    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    June 26, 2025

    Latest News

    • S&P 500 nears record high despite headwinds: key drivers behind the surprise rally
    • Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high
    • S&P 500 nears record high as Wall Street opens higher amid tech momentum

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.